PharmaCyte Biotech, Inc. - Nov 21, 2023 Form 3 Insider Report for FEMASYS INC (FEMY)

Role
10%+ Owner
Signature
/s/ Joshua N. Silverman, Interim President and CEO
Stock symbol
FEMY
Transactions as of
Nov 21, 2023
Transactions value $
$0
Form type
3
Date filed
11/28/2023, 05:06 PM
Next filing
May 30, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FEMY 6.0% Senior Convertible Note due 2025 Nov 21, 2023 Common stock, par value $0.001 per share 4.24M $1.18 Direct
holding FEMY Series A Warrants Nov 21, 2023 Common stock, par value $0.001 per share 4.24M $1.18 Direct
holding FEMY Series B Warrants Nov 21, 2023 Common stock, par value $0.001 per share 4.24M $1.48 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.